FGFR3 biology and skeletal disease

Connective Tissue Research

Volumn 56, Issue 6, 2015, Pages 427-433

  Narayana, Jyoti ^a   Horton, William A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Achondroplasia; bone growth; FGFR3; growth plate; RTK

Indexed keywords

CELL CYCLE PROTEIN 37; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST RECEPTOR FACTOR SUBSTRATE 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOMER; PROTEASOME; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; FGFR3 PROTEIN, HUMAN; FRS2 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ACANTHOSIS NIGRICANS; ACHONDROPLASIA; BONE DEVELOPMENT; BONE DISEASE; BONE GROWTH; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DIMERIZATION; ENCHONDRAL OSSIFICATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; GAIN OF FUNCTION MUTATION; GENE LOCUS; HUMAN; LIGAND BINDING; LOSS OF FUNCTION MUTATION; LYSOSOME; MTT ASSAY; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; THANATOPHORIC DWARFISM; UBIQUITINATION; ANIMAL; BONE TUMOR; DWARFISM; GENETICS; METABOLISM; MUTATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE NEOPLASMS; DWARFISM; HUMANS; MEMBRANE PROTEINS; MUTATION; NEOPLASM PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 84949110019     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.3109/03008207.2015.1051224     Document Type: Review

References (83)

1. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-49
2. Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005; 16: 205-13
3. Ornitz DM, Marie PJ. FGF signaling pathways in endochondrial and intramembranous bone development and human genetic disease. Genes Dev 2002; 16: 1446-65
4. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-25
5. Laederich MB, Horton WA. Achondroplasia: pathogenesis and implications for future treatment. Current Opin Pediatr 2010; 22: 516-23
6. Iyer G, Milowsky MI. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol Oncol 2013; 31: 303-11
7. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125: 105-17
8. Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008; 237: 18-27
9. Degnin CR, Laederich MB, Horton WA. FGFs in endochondral skeletal development. J Cell Biochem 2010; 110: 1046-57
10. Govindraj P, West L, Smith S, Hassell JR. Modulation of FGF-2 binding to chondrocytes from the developing growth plate by perlecan. Matrix Biol 2006; 25: 232-9
11. Smith SM, West LA, Hassell JR. The core protein of growth plate perlecan binds FGF-18 and alters its mitogenic effect on chondrocytes. Arch Biochem Biophys 2007; 468: 244-51
12. Kurosu H, Kuro OM. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2008; 299: 72-8
13. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235-53
14. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000; 6: 743-50
15. Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, Mohammadi M. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 2007; 27: 717-30
16. Chen H, Xu CF, Ma J, Eliseenkova AV, Li W, Pollock PM, Pitteloud N, Miller WT, Neubert TA, Mohammadi M. A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci USA 2008; 105: 19660-5
17. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16: 107-37
18. Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 2001; 12: 931-42
19. Lew ED, Furdui CM, Anderson KS, Schlessinger J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal 2009; 2: ra6
20. Gotoh N, Laks S, Nakashima M, Lax I, Schlessinger J. FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts. FEBS Lett 2004; 564: 14-18
21. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 2008; 99: 1319-25
22. Bottcher RT, Pollet N, Delius H, Niehrs C. The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling. Nat Cell Biol 2004; 6: 38-44
23. Bundschu K, Knobeloch KP, Ullrich M, Schinke T, Amling M, Engelhardt CM, Renne T, Walter U, Schuh K. Gene disruption of Spred-2 causes dwarfism. J Biol Chem 2005; 280: 28572-80
24. Haines BP, Wheldon LM, Summerbell D, Heath JK, Rigby PW. Regulated expression of FLRT genes implies a functional role in the regulation of FGF signalling during mouse development. Dev Biol 2006; 297: 14-25
25. Kovalenko D, Yang X, Chen P-Y, Nadeau RJ, Zubanova O, Pigeon K, Friesel R. A role for extracellular and transmembrane domains of Sef in Sef-mediated inhibition of FGF signaling. Cell Signal 2006; 18: 1958-66
26. Settembre C, Arteaga-Solis E, McKee MD, de Pablo R, Al Awqati Q, Ballabio A, Karsenty G. Proteoglycan desulfation determines the efficiency of chondrocyte autophagy and the extent of FGF signaling during endochondral ossification. Genes Dev 2008; 22: 2645-50
27. Tsang M, Dawid IB. Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. Sci STKE 2004; 2004: pe17
28. Choi DY, Toledo-Aral JJ, Lin HY, Ischenko I, Medina L, Safo P, Mandel G, Levinson SR, Halegoua S, Hayman MJ. Fibroblast growth factor receptor 3 induces gene expression primarily through Ras-independent signal transduction pathways. J Biol Chem 2001; 276: 5116-22
29. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000; 19: 3309-20
30. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 1998; 273: 13007-14
31. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crombrugghe B. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 2004; 18: 290-305
32. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 1999; 13: 1361-6
33. Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, Fu XY. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 1997; 386: 288-92
34. Minina E, Kreschel C, Naski MC, Ornitz DM, Vortkamp A. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 2002; 3: 439-49
35. Zhang R, Murakami S, Coustry F, Wang Y, de Crombrugghe B. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. Proc Natl Acad Sci USA 2006; 103: 365-70
36. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423: 332-6
37. Kronenberg HM, McMahon AP, Tabin CJ. Growth factors and chondrogenesis. In: Pourquie O., ed. The skeletal system. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 2009: 171-203
38. Mugniery E, Dacquin R, Marty C, Benoist-Lasselin C, de Vernejoul MC, Jurdic P, Munnich A, Geoffroy V, Legeai-Mallet L. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth. Hum Mol Genet 2012; 21: 2503-13
39. Ono N, Ono W, Nagasawa T, Kronenberg HM. A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. Nat Cell Biol 2014; 16: 1157-67
40. Yang L, Tsang KY, Tang HC, Chan D, Cheah KS. Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. Proc Natl Acad Sci USA 2014; 111: 12097-102
41. Zhou X, von der Mark K, Henry S, Norton W, Adams H, de Crombrugghe B. Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. PLoS Genet 2014; 10: e1004820
42. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007; 370: 162-72
43. Bellus GA, Hefferon TW, Ortiz de Luna RI, Hecht JT, Horton WA, Machado M, Kaitila I, McIntosh I, Francomano CA. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 1995; 56: 368-73
44. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994; 371: 252-4
45. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994; 78: 335-42
46. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995; 9: 321-8
47. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996; 12: 390-7
48. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84: 911-21
49. Naski MC, Colvin JS, Coffin JD, Ornitz DM. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 1998; 125: 4977-88
50. Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995; 10: 357-9
51. Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 2000; 67: 1411-21
52. Dodurga Y, Tataroglu C, Kesen Z, Satiroglu-Tufan NL. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res 2011; 10: 86-95
53. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014; 34: 280-300
54. Horton WA, Lunstrum GP. Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Rev Endocr Metab Disord 2002; 3: 381-5
55. Laederich M, Horton WA. FGFR3 targeting strategies for achondroplasia. Expert Rev Mol Med 2012; 14: e11
56. Guo C, Degnin CR, Laederich MB, Lunstrum GP, Holden P, Bihlmaier J, Krakow D, Cho Y-J, Horton WA. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia. Cell Signal 2008; 20: 1471-7
57. Monsonego-Ornan E, Adar R, Feferman T, Segev O, Yayon A. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 2000; 20: 516-22
58. Chen L, Adar R, Yang X, Monsonego EO, Li C, Hauschka PV, Yayon A, Deng CX. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J Clin Invest 1999; 104: 1517-25
59. Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 2006; 119: 380-7
60. Chen F, Degnin C, Laederich M, Horton WA, Hristova K. The A391E mutation enhances FGFR3 activation in the absence of ligand. Biochim Biophys Acta 2011; 1808: 2045-50
61. Del Piccolo N, Placone J, Hristova K. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization. Biophys J 2015; 108: 272-8
62. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 2001; 490: 142-52
63. Clague MJ, Urbe S. The interface of receptor trafficking and signalling. J Cell Sci 2001; 114: 3075-81
64. Miaczynska M. Effects of membrane trafficking on signaling by receptor tyrosine kinases. Cold Spring Harbor Persp Biol 2013; 5: a009035
65. Cho JY, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, Horton WA. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 2004; 101: 609-14
66. Laederich MB, Degnin CR, Lunstrum GP, Holden P, Horton WA. Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation. J Biol Chem 2011; 286: 19597-604
67. Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S. hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol 1989; 9: 3919-30
68. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-28
69. Murata S, Chiba T, Tanaka K. CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Int J Biochem Cell Biol 2003; 35: 572-8
70. Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillault A, Diez de Medina SG, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006; 27: 740-7
71. Li C, Chen L, Iwata T, Kitagawa M, Fu XY, Deng CX. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet 1999; 8: 35-44
72. Laederich MB. Defining the role of Hsp90 in the stability of FGFR3 and as a drug target for the treatment of skeletal diseases and cancer. Portland, OR: Oregon Health & Science University; 2011
73. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000; 100: 391-8
74. Kopan R, Ilagan MX. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 2004; 5: 499-504
75. Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 2003; 15: 143-8
76. Ancot F, Foveau B, Lefebvre J, Leroy C, Tulasne D. Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity. Oncogene 2009; 28: 2185-95
77. Carpenter G, Liao HJ. Trafficking of receptor tyrosine kinases to the nucleus. Exp Cell Res 2009; 315: 1556-66
78. Jurisch-Yaksi N, Sannerud R, Annaert W. A fast growing spectrum of biological functions of gamma-secretase in development and disease. Biochim Biophys Acta 2013; 1828: 2815-27
79. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294: 2179-81
80. Blobel CP, Carpenter G, Freeman M. The role of protease activity in ErbB biology. Exp Cell Res 2009; 315: 671-82
81. Degnin CR, Laederich MB, Horton WA. Ligand activation leads to regulated intramembrane proteolysis (RIP) of Fibroblast Growth Factor Receptor 3. Mol Biol Cell 2011; 22: 3861-3873
82. Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 2008; 65: 1311-34
83. Laederich MB, and, Horton WA. FGFR3 targeting strategies for achondroplasia. Exp Rev Mol Med 2012; 14: e11